Juan-Pablo MasPartner at Action Potential VC
Juan-Pablo is a partner at Action Potential Venture Capital (APVC) in Palo Alto, CA, and invests in companies developing bioelectronic medicines, and is looking at select technology enabled healthcare companies. Juan-Pablo is a Board member of Saluda Medical, SetPoint Medical, Neuspera Medical, Cala Health, CVRx, and Presidio Medical. He was previously an investor at Morgenthaler Ventures and Lightstone Ventures. There he served as a Board observer at Ardian (acquired by Medtronic), Twelve (acquired by Medtronic), Nuvaira, Cabochon Aesthetics (acquired by Ulthera/Merz), and Miramar Labs (acquired by Sientra).
Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronic’s CardioVascular Division, including Pipeline Strategy, Business Development, and M&A integration efforts. He was named “Medtronic Inventor of The Year” in 2008, and has 30+ patents, granted or pending. Subsequently, he served on the Global Brand Strategy team at Eli Lilly within the Cardiovascular business.
Juan-Pablo earned an MBA from Stanford GSB, an M.S. in Electrical Engineering from Stanford, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanford University’s Neuroscience Institute (Wu Tsai), the VC/BD Committee of AdvaMed Accel, the Advisory Board for UCSF’s Rosenman Institute, and is a founding Board Member of LatinxVC. He played Division I men’s lacrosse at the University of Massachusetts, and is originally from Puerto Rico.